You are here: Industry Insights > BMS

News List

BMS' Opdivo becomes first immuno-oncology agent available in China pharmafile
June 22, 2018
Bristol-Myers Squibb’s flagship immunotherapy Opdivo (nivolumab) has broken ground to become the first and only PD-1 inhibitor to be made available in China.
BMS’ Opdivo cuts risk of melanoma recurrence pharmatimes
June 06, 2018
Bristol-Myers Squibb’s Opdivo, which is being investigated as adjuvant treatment after surgery for stage IIIb/c or IV melanoma patients at high risk of recurrence
BMS looks to leverage real-world data, with Flatiron collab pharmafile
May 04, 2018
Bristol-Myers Squibb has extended its existing collaboration with Flatiron Health by three years and expanded the efforts both will be making in using real-world data in cancer research.
BMS pulls the plug on Phase 3 trials of IDO1 inhibitor pharmafile
May 03, 2018
Bristol-Myers Squibb has terminated two pivotal Phase 3 trials of BMS-986205, an IDO1 inhibitor acquired through its $800 million acquisition ...
BMS’ Opdivo to Become the First Anti-PD-(L)1 Antibody to Enter China Dopine
April 27, 2018
According to the latest clinical trial data of the CheckMate-078 (NCT02613507, CTR20150767) of Opdivo (nivolumab) conduc
Novartis snatches Amgen and BMS veteran for CMO and Drug Development Head pharmafile
April 20, 2018
Dr John Tsai has been welcomed to the fold as Novartis’ new Head of Global Development and Chief Medical Officer, stepping into the role vacated by Dr Vas Narasimhan, who has since taken up the mantle of CEO at the company.
‘Keytruda is King’ in lung cancer, putting BMS and next-gen in the shade pharmaphorum
April 18, 2018
Merck & Co is pressing home its precious advantage in first line non-small cell lung cancer, with new data from a Keytruda + chemo combination suggesting patients’ lives could be significantly extended.
BMS begins Harvard fibrosis stem cell research collaboration pharmaphorum
April 16, 2018
Bristol-Myers Squibb has begun a research collaboration with a group stem cell experts from Harvard University into fibrotic diseases, including fibrosis of the liver and heart.
Biohaven, BMS Restructure Migraine Alliance contractpharma
March 13, 2018
Biohaven Pharmaceutical is restructuring its global license agreement with Bristol-Myers Squibb Co. for Biohaven's small molecule calcitonin gene-related peptide (CGRP) receptor antagonist platform
PsiOxus Achieves $15M BMS Milestone contractpharma
December 13, 2017
PsiOxus Therapeutics’ Clinical Trial Application for NG-348, an “armed” oncolytic virus for the treatment of solid tumors, has been approved, triggering a $15 million milestone payment from development partner, Bristol-Myers Squibb.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page